Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

被引：0
|
作者：
Manley, Paul W. [1 ]
Cowan-Jacob, Sandra W. [1 ]
Cozens, Robert [1 ]
Fendrich, Gabriele [1 ]
Jahnke, Wolfgang [1 ]
Roesel, Johannes L. [1 ]
Fabbro, Dorian [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1181 / 1181
页数：1
相关论文
共 50 条
  • [31] The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
    M Stanglmaier
    M Warmuth
    I Kleinlein
    S Reis
    M Hallek
    Leukemia, 2003, 17 : 283 - 289
  • [32] FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway
    Li, Mei-Hong
    Hla, Timothy
    Ferrer, Fernando
    PEDIATRIC BLOOD & CANCER, 2013, 60 (09) : 1418 - 1423
  • [33] Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38- Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL-independent Signals
    Neviani, Paolo
    Santhanam, Ramasamy
    Ma, Yihui
    Marcucci, Guido
    Byrd, John C.
    Chen, Ching-Shih
    Cortes, Jorge
    Caligiuri, Michael A.
    Huettner, Claudia
    Bhatia, Ravi
    Roy, Denis-Claude
    Perrotti, Danilo
    BLOOD, 2008, 112 (11) : 77 - 77
  • [34] NMR Assignment Reveals an α-Helical Fold for the F-Actin Binding Domain of Human Bcr-Abl/c-Abl
    Silke Wiesner
    Oliver Hantschel
    Cameron D. Mackereth
    Giulio Superti-Furga
    Michael Sattler
    Journal of Biomolecular NMR, 2005, 32 : 335 - 335
  • [35] NMR assignment reveals an α-helical fold for the F-actin binding domain of human Bcr-Abl/c-Abl
    Wiesner, S
    Hantschel, O
    Mackereth, CD
    Superti-Furga, G
    Sattler, M
    JOURNAL OF BIOMOLECULAR NMR, 2005, 32 (04) : 335 - 335
  • [36] Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments
    Laurini, Erik
    Posocco, Paola
    Fermeglia, Maurizio
    Gibbons, Don L.
    Quintas-Cardama, Alfonso
    Pricl, Sabrina
    MOLECULAR ONCOLOGY, 2013, 7 (05) : 968 - 975
  • [37] Enhanced and Selective Killing of Chronic Myelogenous Leukemia Cells with an Engineered BCR-ABL Binding Protein and Imatinib
    Constance, Jonathan E.
    Woessner, David W.
    Matissek, Karina J.
    Mossalam, Mohanad
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2012, 9 (11) : 3318 - 3329
  • [38] Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
    Skaggs, Brian J.
    Gorre, Mercedes E.
    Ryvkin, Ann
    Burgess, Michael R.
    Xie, Yongming
    Han, Yun
    Komisopoulou, Evangelia
    Brown, Lauren M.
    Loo, Joseph A.
    Landaw, Elliot M.
    Sawyers, Charles L.
    Graeber, Thomas G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (51) : 19466 - 19471
  • [39] VASP Protein, a Binding Partner Of BCR-ABL and FAK, May Be Implicated In The Chronic Myeloid Leukemia Phenotype
    Bernusso, Vanessa Aline
    Machado-Neto, Joao Agostinho
    Pericole, Fernando V.
    Vieira, Karla Priscila
    Duarte, Adriana Silva Santos
    Traina, Fabiola
    Hansen, Marc D.
    Saad, Sara Teresinha Olalla
    Barcellos, Karin Spat Albino
    BLOOD, 2013, 122 (21)
  • [40] ATP binding domain mutants of BCR-ABL in patients with chronic myeloid leukemia treated with imatinib.
    Liu, XL
    Zhang, S
    Du, QF
    Fan, W
    Wang, Y
    Yao, F
    BLOOD, 2005, 106 (11) : 294B - 294B
12345